248 related articles for article (PubMed ID: 22171699)
1. Predominant or complete recipient T-cell chimerism following alemtuzumab-based allogeneic transplantation is reversed by donor lymphocytes and not associated with graft failure.
Mohamedbhai SG; Edwards N; Morris EC; Mackinnon S; Thomson KJ; Peggs KS
Br J Haematol; 2012 Feb; 156(4):516-22. PubMed ID: 22171699
[TBL] [Abstract][Full Text] [Related]
2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
3. Post-transplant T cell chimerism predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab based reduced intensity conditioned allogeneic transplant.
Nikolousis E; Robinson S; Nagra S; Brookes C; Kinsella F; Tauro S; Jeffries S; Griffiths M; Mahendra P; Cook M; Paneesha S; Lovell R; Kishore B; Chaganti S; Malladi R; Raghavan M; Moss P; Milligan D; Craddock C
Leuk Res; 2013 May; 37(5):561-5. PubMed ID: 23395505
[TBL] [Abstract][Full Text] [Related]
4. Long-term follow-up of persisting mixed chimerism after partially T cell-depleted allogeneic stem cell transplantation.
Schaap N; Schattenberg A; Mensink E; Preijers F; Hillegers M; Knops R; Pennings A; Boezeman J; Geurts van Kessel A; de Pauw B; de Witte T
Leukemia; 2002 Jan; 16(1):13-21. PubMed ID: 11840258
[TBL] [Abstract][Full Text] [Related]
5. Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.
El-Cheikh J; Vazquez A; Crocchiolo R; Furst S; Calmels B; Castagna L; Lemarie C; Granata A; Ladaique P; Oudin C; Faucher C; Chabannon C; Blaise D
Am J Hematol; 2012 Dec; 87(12):1074-8. PubMed ID: 22911907
[TBL] [Abstract][Full Text] [Related]
6. Early recipient chimerism testing in the T- and NK-cell lineages for risk assessment of graft rejection in pediatric patients undergoing allogeneic stem cell transplantation.
Breuer S; Preuner S; Fritsch G; Daxberger H; Koenig M; Poetschger U; Lawitschka A; Peters C; Mann G; Lion T; Matthes-Martin S
Leukemia; 2012 Mar; 26(3):509-19. PubMed ID: 21926962
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity transplantation with in vivo T-cell depletion and adjuvant dose-escalating donor lymphocyte infusions for chemotherapy-sensitive myeloma: limited efficacy of graft-versus-tumor activity.
Peggs KS; Mackinnon S; Williams CD; D'Sa S; Thuraisundaram D; Kyriakou C; Morris EC; Hale G; Waldmann H; Linch DC; Goldstone AH; Yong K
Biol Blood Marrow Transplant; 2003 Apr; 9(4):257-65. PubMed ID: 12720218
[TBL] [Abstract][Full Text] [Related]
8. Mixed chimera converted into full donor chimera with powerful graft-versus-leukemia effects but no graft-versus-host disease after non T cell-depleted HLA-mismatched peripheral blood stem cell transplantation.
Wu BY; Guo KY; Song CY; Yang ; Li D
Bone Marrow Transplant; 2000 Sep; 26(6):691-3. PubMed ID: 11035376
[TBL] [Abstract][Full Text] [Related]
9. Induction of stable long-term mixed hematopoietic chimerism following nonmyeloablative conditioning with T cell-depleting antibodies, cyclophosphamide, and thymic irradiation leads to donor-specific in vitro and in vivo tolerance.
Mapara MY; Pelot M; Zhao G; Swenson K; Pearson D; Sykes M
Biol Blood Marrow Transplant; 2001; 7(12):646-55. PubMed ID: 11787527
[TBL] [Abstract][Full Text] [Related]
10. Rapid establishment of long-term culture-initiating cells of donor origin after nonmyeloablative allogeneic hematopoietic stem-cell transplantation, and significant prognostic impact of donor T-cell chimerism on stable engraftment and progression-free survival.
Keil F; Prinz E; Moser K; Mannhalter C; Kalhs P; Worel N; Rabitsch W; Schulenburg A; Mitterbauer M; Greinix H
Transplantation; 2003 Jul; 76(1):230-6. PubMed ID: 12865815
[TBL] [Abstract][Full Text] [Related]
11. Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
Meyer RG; Wagner EM; Konur A; Bender K; Schmitt T; Hemmerling J; Wehler D; Hartwig UF; Roosnek E; Huber C; Kolbe K; Herr W
Bone Marrow Transplant; 2010 Apr; 45(4):668-74. PubMed ID: 19684624
[TBL] [Abstract][Full Text] [Related]
12. Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs KS; Sureda A; Qian W; Caballero D; Hunter A; Urbano-Ispizua A; Cavet J; Ribera JM; Parker A; Canales M; Mahendra P; Garcia-Conde J; Milligan D; Sanz G; Thomson K; Arranz R; Goldstone AH; Alvarez I; Linch DC; Sierra J; Mackinnon S;
Br J Haematol; 2007 Oct; 139(1):70-80. PubMed ID: 17854309
[TBL] [Abstract][Full Text] [Related]
13. Competitive Repopulation and Allo-Immunologic Pressure Determine Chimerism Kinetics after T Cell-Depleted Allogeneic Stem Cell Transplantation and Donor Lymphocyte Infusion.
Koster EAS; von dem Borne PA; van Balen P; van Egmond EHM; Marijt EWA; Veld SAJ; Jedema I; Snijders TJF; van Lammeren D; Veelken H; Falkenburg JHF; de Wreede LC; Halkes CJM
Transplant Cell Ther; 2023 Apr; 29(4):268.e1-268.e10. PubMed ID: 36587743
[TBL] [Abstract][Full Text] [Related]
14. [Clinical significance of dynamic monitoring of cell chimerism following allogeneic hematopoietic stem cell transplantation].
Jiang Y; Wan LP; Wang C; Yan SK; Gao YR; Jiang JL; Yang J; Cai Y; Bai HT; Wei DL; Xie KC
Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):667-71. PubMed ID: 19176059
[TBL] [Abstract][Full Text] [Related]
15. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
Karasu GT; Yesilipek MA; Karauzum SB; Uygun V; Manguoglu E; Kupesiz A; Hazar V
Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066
[TBL] [Abstract][Full Text] [Related]
16. [An analysis of leukocyte subsets chimerism following allogeneic peripheral blood stem cell transplantation].
Wan LP; Wang C; Yan SK; Li DQ; Qin YW; Xie KC
Zhonghua Nei Ke Za Zhi; 2006 Jun; 45(6):485-8. PubMed ID: 16831328
[TBL] [Abstract][Full Text] [Related]
17. Correlation between the kinetics of CD3+ chimerism and the incidence of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation.
Rupa-Matysek J; Lewandowski K; Nowak W; Sawiński K; Gil L; Komarnicki M
Transplant Proc; 2011 Jun; 43(5):1915-23. PubMed ID: 21693300
[TBL] [Abstract][Full Text] [Related]
18. Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells.
Grimaldi F; Potter V; Perez-Abellan P; Veluchamy JP; Atif M; Grain R; Sen M; Best S; Lea N; Rice C; Pagliuca A; Mufti GJ; Marsh JCW; Barber LD
Biol Blood Marrow Transplant; 2017 Feb; 23(2):293-299. PubMed ID: 27816648
[TBL] [Abstract][Full Text] [Related]
19. Stable mixed chimerism after T cell-depleted allogeneic hematopoietic stem cell transplantation using conditioning with low-dose total body irradiation and fludarabine.
Görner M; Kordelas L; Thalheimer M; Luft T; Pfeiffer S; Ustaoglu F; Punzel M; Weber-Nordt R; Moos M; Goldschmidt H; Ho AD
Bone Marrow Transplant; 2002 Apr; 29(7):621-4. PubMed ID: 11979314
[TBL] [Abstract][Full Text] [Related]
20. Mixed allogeneic chimerism in the rat. Donor-specific transplantation tolerance without chronic rejection for primarily vascularized cardiac allografts.
Colson YL; Zadach K; Nalesnik M; Ildstad ST
Transplantation; 1995 Nov; 60(9):971-80. PubMed ID: 7491703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
